Research priorities for COVID-19 sensor technology

Tong, Allison; Sorrell, Tania C.; Black, Andrew J.; Caillaud, Corinne; Chrzanowski, Wojciech; Li, Eugena; Martínez-Martín, David; McEwan, Alistair; Wang, Rex; Motion, Alice; Casas-Bedoya, Alvaro; Huang, Jun; Azizi, Lamiae; Eggleton, Benjamin J.

doi:10.1038/s41587-021-00816-8

Cited by 33 publications

(26 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the simplicity of the assay, the reported LFIA can be used for self-testing in point-of-need conditions and as a complementary test to PCR. Such rapid and easy-to-use tests are in demand by public health [40]. LFIA antigen tests have already shown promising performance for mass population screening [41].…”

Section: Validation Of Lfia In Testing Samples With Inactivated Sars-cov-2 Virionsmentioning

confidence: 99%

Comparative Study of In Situ Techniques to Enlarge Gold Nanoparticles for Highly Sensitive Lateral Flow Immunoassay of SARS-CoV-2

et al. 2021

View full text Add to dashboard Cite

Three techniques were compared for lowering the limit of detection (LOD) of the lateral flow immunoassay (LFIA) of the receptor-binding domain of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) based on the post-assay in situ enlargement of Au nanoparticles (Au NPs) on a test strip. Silver enhancement (growth of a silver layer over Au NPs—Au@Ag NPs) and gold enhancement (growth of a gold layer over Au NPs) techniques and the novel technique of galvanic replacement of Ag by Au in Au@Ag NPs causing the formation of Au@Ag-Au NPs were performed. All the enhancements were performed on-site after completion of the conventional LFIA and maintained equipment-free assay. The assays demonstrated lowering of LODs in the following rows: 488 pg/mL (conventional LFIA with Au NPs), 61 pg/mL (silver enhancement), 8 pg/mL (galvanic replacement), and 1 pg/mL (gold enhancement). Using gold enhancement as the optimal technique, the maximal dilution of inactivated SARS-CoV-2-containing samples increased 500 times. The developed LFIA provided highly sensitive and rapid (8 min) point-of-need testing.

show abstract

Section: Validation Of Lfia In Testing Samples With Inactivated Sars-cov-2 Virionsmentioning

confidence: 99%

Comparative Study of In Situ Techniques to Enlarge Gold Nanoparticles for Highly Sensitive Lateral Flow Immunoassay of SARS-CoV-2

et al. 2021

View full text Add to dashboard Cite

show abstract

“…There are many different variants of it, and most of their variants spread rapidly and cause infection at human respiratory tract, which ultimately leads to serious respiratory illness, resulting in extremely high morbidity and even death. The global COVID-19 pandemic is caused by the spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) 1 – 4 . Nearly 372 million people have tested positive worldwide and nearly 5.6 million people have lost their lives due to this deadly outbreak till February 2022.…”

Section: Introductionmentioning

confidence: 99%

E.Co.Tech-electrochemical handheld breathalyzer COVID sensing technology

Banga

Paul

France³

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Breathomics is widely emerging as a strategy for non-invasive diagnosis of respiratory inflammation. In this study, we have evaluated the metabolic signals associated with Coronavirus (SARS COV-2), mainly the release of nitric oxide in breath. We have demonstrated the utility of a breath analyzer-based sensor platform for the detection of trace amounts of this target species. The sensor surface is modified with Room Temperature Ionic Liquid (RTIL) that allows faster diffusion of the target gas and can be used for gas sensing application. A low limit of detection (LOD) of 50 parts per billion has been achieved with a 95% confidence interval for detection of nitric oxide.. This inhouse designed sensor is incorporated into a breath analyzer system that displays enhanced sensitivity, specificity, linearity, and reproducibility for NO gas monitoring. The developed sensor platform can detect target concentrations of NO ranging from 50 to 250 ppb, using 1-Ethyl-3-methylimidazolium Tetrafluoroborate ([EMIM]BF4) as RTIL and displays fast response time of 5 s, thereby allowing easy detection of the target gas species. The sensor successfully quantifies the diffusion current and charge modulations arising within the electrical double layer from the RTIL–NO interactions through DC-based chronoamperometry (CA). The subjects tested negative and positive are significantly different (p < 0.01). The prototype can potentially be used for human health monitoring and screening, especially during the pandemic due to its portability, small size, an embedded RTIL sensing element, integrability with a low-power microelectronic device, and an IoT interface.

show abstract

“…THE need for sensitive, quick and compact diagnostic platforms for instant screening of infectious diseases has been brought into sharp focus by the COVID-19 pandemic [ 1 ], [ 2 ]. Integrated microfluidic biosensors can detect different biomarkers, e.g., nucleic acids and proteins, from bodily fluids and have shown potential to be implemented as customized point of care (POC) platforms in case of outbreaks [ 3 ]–[ 7 ].…”

Section: Introductionmentioning

confidence: 99%

FPGA Integrated Optofluidic Biosensor for Real-Time Single Biomarker Analysis

et al. 2022

View full text Add to dashboard Cite

Integrated optofluidic biosensors can fill the need for sensitive, amplification-free, multiplex single molecule detection which is relevant for containing the spread of infectious diseases such as COVID-19. Here, we demonstrate a rapid sample-to-answer scheme that uses a field programmable gate array (FPGA) to enable live monitoring of single particle fluorescence analysis on an optofluidic chip. Fluorescent nanobeads flowing through a micro channel are detected with 99% accuracy and particle concentrations in clinically relevant ranges from 3.4×10 4 to 3.4 × 10 6 /ml are determined within seconds to a few minutes without the need for post-experiment data extraction and analysis. In addition, other extract salient experimental parameters such as dynamic flow rate changes can be monitored in real time. The sensor is validated with real-time fluorescence detection of single bacterial plasmid DNA at attomolar concentrations, showing excellent promise for implementation as a point of care (POC) diagnostic tool.

show abstract

Research priorities for COVID-19 sensor technology

Cited by 33 publications

References 9 publications

Comparative Study of In Situ Techniques to Enlarge Gold Nanoparticles for Highly Sensitive Lateral Flow Immunoassay of SARS-CoV-2

Comparative Study of In Situ Techniques to Enlarge Gold Nanoparticles for Highly Sensitive Lateral Flow Immunoassay of SARS-CoV-2

E.Co.Tech-electrochemical handheld breathalyzer COVID sensing technology

FPGA Integrated Optofluidic Biosensor for Real-Time Single Biomarker Analysis

Contact Info

Product

Resources

About